long acting versus intermediate acting insulin for patients with type 1 diabetes
Read the open access research:
This systematic review by Andrea Tricco and colleagues sets out to answer the question, are newer, longer lasting insulin analogues better than isophane insulin and zinc insulin, which have been commonly used since the 1950s for treating type 1 diabetes?
Tricco et al suggest that newer insulin analogues are probably superior to intermediate acting insulin analogues, although the difference is small for haemoglobin A1c. Patients and their physicians should tailor their choice of insulin according to preference, cost, and accessibility.